VerImmune
VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.
2
Funding Rounds
$7.0m
Money raised
Funding
Funding series
Funding Series Analysis
The company VerImmune has raised a total of $7m in funding over 2 rounds.
Key Insights:
- VerImmune September 2024 Seed Funding Round: $4.5m
- VerImmune, Inc. Funding Round, March 2022: $2.5m
VerImmune September 2024 Seed Funding Round
$4.5m
VerImmune, Inc. Funding Round, March 2022
$2.5m